IN Brief:
- PCB Technologies was awarded the medical-industry tender on 23 August.
- The company estimates approximately $65 million of sales during 2027 and 2028.
- The unnamed customer is an existing client and retains the right to change ordered quantities.
PCB Technologies has secured a medical electronics tender expected to generate approximately $65 million in sales during 2027 and 2028, extending an existing manufacturing relationship with an unnamed global customer.
The Israeli electronics manufacturer was awarded the tender on 23 August for the supply of electronic packaging products over the two-year period. PCB Technologies describes the customer as a leading company in the medical industry and confirms that it already supplies the organisation.
The $65 million figure is an estimate rather than a fixed purchase commitment. The customer retains the right to change the quantities ordered, meaning the eventual value of shipments can move above or below the figure disclosed with the award.
That caveat matters because the announcement is fundamentally a forward manufacturing programme rather than booked revenue. PCB Technologies will recognise the commercial value only as customer orders are released, products are manufactured, and deliveries take place during 2027 and 2028.
The company’s manufacturing operations span complex multilayer printed circuit boards, rigid-flex and flexible circuits, PCB assembly, advanced substrates, IC packaging, electromechanical integration, and testing. Its iNPACK subsidiary extends that capability into miniaturised organic substrates and system-in-package work.
Medical electronics can make use of several of those technologies within the same product. A diagnostic or surgical system may combine processors, analogue sensing, communications, power conversion, high-speed interfaces, and electromechanical assemblies, while wearable and implantable devices impose much tighter constraints on PCB area and interconnection.
PCB Technologies lists ISO 13485 certification for its medical manufacturing operation. The standard concerns quality-management systems for medical-device organisations, bringing additional emphasis to traceability, documentation, controlled processes, and risk management rather than acting as approval for an individual electronic assembly.
The company also promotes high-density interconnect, rigid-flex construction, controlled-impedance routing, and advanced packaging for medical applications. Rigid-flex designs can eliminate some connectors and cable assemblies where electronics must fit inside compact or irregular enclosures, while HDI structures allow finer routing and denser component placement.
None of those technologies has been identified specifically for the new customer programme, so there is no basis for assigning a particular PCB stack-up or packaging process to the tender. The disclosed development is the scale and duration of the manufacturing award rather than a newly announced device architecture.
That still makes it relevant to the electronics supply chain. Medical customers typically require stable production processes, controlled component sourcing, traceability, testing, and long product lifecycles, and the resulting programmes can continue long after an individual semiconductor generation would have disappeared from consumer equipment.
For an electronics manufacturer, this creates a different production problem from chasing maximum unit volume. High-mix medical work can involve complex assemblies, smaller production batches, specialised inspection, documentation, and sustained component support alongside the need to control cost.
PCB Technologies positions its operation around bringing several of those stages under one manufacturing organisation. Its services include PCB fabrication, component sourcing, assembly, testing, system integration, thermal management, and design-for-manufacture support, reducing the number of external manufacturing interfaces a customer has to coordinate.
The new tender also illustrates how advanced packaging and conventional PCB assembly are beginning to overlap. As medical electronics become smaller and more computationally capable, designers can move some integration from the board towards substrates, modules, and package-level assemblies while retaining larger PCBs for power, connectors, and system interconnection.
The manufacturer has not named the customer, products, annual shipment quantities, or production mix associated with the programme. Those omissions limit the technical conclusions that can reasonably be drawn from the award, and the stated $65 million remains explicitly subject to changes in ordered quantities.
What has been established is a two-year forward commitment from an existing medical-sector customer to an electronics supplier with PCB, assembly, and packaging capability. The more revealing figures will emerge during 2027 and 2028, when order releases show how much of the estimated value converts into actual production.
